CGS-authored

SAN FRANCISCO - During the campaign for California's $3 billion stem cell initiative, supporters predicted as much as $1 billion would be returned to state coffers through royalties from stem cell therapies.

But now, some question whether the state will get a dime.

Federal tax laws may prevent California from requiring companies to share royalties if the state issues tax-exempt bonds to finance the program, experts testified Monday.

That leaves stem cell leaders in a quandary: Do they issue taxable bonds -- at an added cost to taxpayers of $420 million to $700 million because of higher interest rates -- in exchange for negotiated agreements on royalties that may or may not materialize?

Or do they abandon the royalties idea and risk alienating voters? Is there a third possibility -- some other way to ensure Californians reap benefits from their huge investment, maybe by getting reduced prices on treatments for low-income Californians?

"This really is, fundamentally, a debate around the accountability to taxpayers," said Jean Ross, executive director of the California Budget Project.

Taxpayers should not be asked to pay...